

Vermont Vaccine Purchasing Program Assessment Calculation Worksheet

Column →	A		B	C		D	E
	CHILDREN			ADULTS			
Line ↓	Prior July 2022	July 2023-June 2024		Prior July 2022	July 2023-June 2024		Comments
A. Preliminary Vaccine Cost Estimates							
01.	15,533,777	20,774,216		7,098,370	11,662,098		Estimated costs of vaccines (sheets e & f)
02.	77,669	103,871	0.50%	35,492	58,310	0.50%	Provision for vaccine utilization increase
03.	0	0	0.00%	249,685	410,214	3.50%	¹ Provision for vaccine cost increase (% is annual)
04.	15,611,446	20,878,087		7,383,547	12,130,623		Est. vaccines costs(w/utilization & price adjustments.)
05.	-8,543,577	-11,218,077		-338,378	-323,378		Estimated VFC Award & 317 federal grant
06.	0	0		0	0		Other
07.	7,067,869	9,660,010		7,045,169	11,807,245		Total estimated VVPP vaccine costs
B. Assessable Covered Lives Estimates							
08.	57,498	57,161		345,729	351,506		Assessable covered lives (sheet c)
09.	0	0	0.00%	0	0	0.00%	Leakage (unknown insurer, out of reach entity, etc.)
10.	57,498	57,161		345,729	351,506		Assessable lives actually paying
C. Financial Carry Forwards							
11.	568,455	849,010		478,392	846,283		Vaccine fund carryforward (sheet d.)
12.	0	0	0.0	0	0	0.0	Amt. retained for liquidity reserve /reserve months
13.	568,455	849,010		478,392	846,283		Carryforward to reduce (add to) current assessment
D. Operational and Other Fixed Costs							
14.	261,511	357,420	3.70%	260,671	436,868	3.70%	VDH operational cost
15.	117,936	112,091		119,097	139,347		Administrative fees - KidsVax (from sheet b.)
16.	733	1,002	0.01%	731	1,224	0.01%	Bad debt allowance
17.	380,180	470,513		380,499	577,439		Sub-total anticipated operating costs
18.	0	0	0.00%	0	0	0.00%	Working capital reserve build-up
19.	0	0	0.00%	0	0	0.00%	Risk reserves
20.	<u>\$ 380,180</u>	<u>\$ 470,513</u>		<u>\$ 380,499</u>	<u>\$ 577,439</u>		Total fixed costs
E. Assessment Calculation							
21.	\$ 7,448,049	\$ 10,130,523		\$ 7,425,668	\$ 12,384,684		Total assessment funds needed (Line 7 + Line 20)
22.	\$ (568,455)	\$ (849,010)		\$ (478,392)	\$ (846,283)		Plus carry forward credit
23.	<u>\$ 6,879,594</u>	<u>\$ 9,281,514</u>		<u>\$ 6,947,276</u>	<u>\$ 11,538,401</u>		Net assessment funds needed
F. Per Assessable Covered Life Assessment							
24.	\$119.76	\$162.48		\$20.16	\$32.88		Annual assessment per covered life
25.	\$9.98	\$13.54		\$1.68	\$2.74		Monthly assessment per covered life calculated
26.	\$9.98	\$13.54		\$1.68	\$2.74		Monthly assessment per covered life recommended
G. Unexpended Assessments							
27.	733	1,002		731	1,224		² Unexpended assessments
H. Various Performance Metrics							
28.	1.67%	1.16%		1.69%	1.18%		Administrative fees - KidsVax as % of vaccine costs
29.	5.37%	4.86%		5.39%	4.88%		VDH operational cost & KV admin. fee as a % of vaccines
30.	-16.97%	35.67%		-1.18%	63.10%		% year to year change in assessment rate
31.	\$ 10.79	\$14.77		\$1.79	\$2.94		³ "Normalized" assessment rate (w/o lines 11, & 18)
32.	8.2%	9.1%		6.5%	7.2%		% Change from monthly assessment rate
33.	\$ 10.96	\$15.05		\$1.82	\$3.00		⁴ Preliminary Assessment projection
34.	9.8%	11.2%		8.4%	9.6%		Preliminary Assessment increase
I. Vaccine Cost per Covered Life determination							
35.	\$ 122.88	\$ 168.96		\$ 20.40	\$ 33.60		Annual vaccine cost calculated
36.	\$ 10.24	\$ 14.08		\$ 1.70	\$ 2.80		Monthly vaccine cost calculated

Notes:

- ¹ The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines.
The child price increase is 0 on Line 3 because VDH anticipates purchasing vaccines administered in April-June 2023 in March 2023, at April 2022 prices. All childhood vaccine cost projections are based on April 2023 CDC pricing.
The line 3 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2023 CDC prices.
- ² Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.
- ³ This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.
- ⁴ Preliminary projection: This is the normalized assessment rate and one additional year of inflation and utilization changes.

**Vermont Vaccine Purchasing Program
Budget Estimates and Allocations**

Line ↓	Column →	A	B	C	D	E	F	G	H
				CHILDREN				ADULT	
		Prior Year	Unallocated ¹	Specific	Allocated ¹	Total	Specific	Allocated ¹	Total
01.	Administrative Fees (KidsVax®)								
02.	Annual Base Fee	\$237,033	\$251,438 ²		\$112,091	\$112,091		\$139,347	\$139,347
03.	Expense Allowance (travel)	\$0	\$0 ⁵		\$0	\$0		\$0	\$0
04.	Other	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
05.	Subtotal	\$237,033	\$251,438	\$0	\$112,091	\$112,091	\$0	\$139,347	\$139,347
	General Expenses								
06.	Bank Fees & Service Charges				\$0	\$0		\$0	\$0
07.	Auditing Fees				\$0	\$0		\$0	\$0
08.	Legal Fees				\$0	\$0		\$0	\$0
09.	VVPP Miscellaneous Expenses				\$0	\$0		\$0	\$0
10.	Office Expense				\$0	\$0		\$0	\$0
11.	Telephone Expense				\$0	\$0		\$0	\$0
12.	Postage and Shipping Expense				\$0	\$0		\$0	\$0
13.	Significant Website Enhancement				\$0	\$0		\$0	\$0
14.	Public Information Expense (other than web site)				\$0	\$0		\$0	\$0
15.	Insurance Expense (D&O)				\$0	\$0		\$0	\$0
16.	Printing Expense				\$0	\$0		\$0	\$0
17.	Publications				\$0	\$0		\$0	\$0
18.	Travel Expense				\$0	\$0		\$0	\$0
19.	Meeting Expense		\$0	\$0	\$0	\$0	\$0	\$0	\$0
20.	Subtotal	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
	Special Projects								
21.					\$0	\$0		\$0	\$0
22.					\$0	\$0		\$0	\$0
23.			\$0	\$0	\$0	\$0	\$0	\$0	\$0
24.	Subtotal		\$0	\$0	\$0	\$0	\$0	\$0	\$0
25.	Total Expenses	<u>\$237,033</u>	<u>\$251,438</u>	<u>\$0</u>	<u>\$112,091</u>	<u>\$112,091</u>	<u>\$0</u>	<u>\$139,347</u>	<u>\$139,347</u>

NOTES:

¹ "Unallocated" in this spreadsheet means that the specific item is not specific to either child or adult vaccines. If no other rule is given, allocation will be based upon the ratio of the child & adult total vaccine costs, plus VDH administrative fees (tab a. line 14), plus any carry forward credit or debit (tab a. line 13), respectively, to the total. That computation is as follows:

total child: 9,168,421 total adult: 11,397,830 44.58% is the child % of total

² Comprehensive fee for the upcoming fiscal year.

³ No plans for implementation of lockbox.

⁴ Actual costs, if any. Presently expected to be zero.

⁵ Bundled in KidsVax comprehensive fee for normal amounts.

Vermont Vaccine Purchasing Program
Estimated Covered Lives for Assessment Calculation

Covered lives reported to KV for the historical quarter:

Column →	A	B	C		D	E	F		G	H		I	J		K	L		M
Line ↓	Assessme	Membership	Quarter		Kids	Adults	Kids	Adults	Total	Kids	Adults	Quarterly Variance	Monthly Average (using 12 months)		Kids	Adults	R12 Trend	
	Quarte	Period	Kids	Adults	Kids	Adults	Kids	Adults	Total	Kids	Adults		Kids	Adults	Kids	Adults	Kids	Adults
01.	Q1	1/2019-3/2019	178,304	1,024,917	59,435	341,639	401,074	-0.9%	0.6%	59,595	342,395	2.6%	-0.2%					
02.	Q2	4/2019-6/2019	179,777	1,016,235	59,926	338,745	398,671	0.8%	-0.8%	59,634	340,656	1.9%	-0.7%					
03.	Q3	7/2019-9/2019	179,153	1,005,968	59,718	335,323	395,040	-0.3%	-1.0%	59,760	338,820	1.5%	-1.3%					
04.	Q4	10/2019-12/2019	180,310	1,002,208	60,103	334,069	394,173	0.6%	-0.4%	59,795	337,444	0.8%	-1.7%					
05.	Q1	1/2020-3/2020	180,326	1,006,742	60,109	335,581	395,689	0.0%	0.5%	59,964	335,929	0.6%	-1.9%					
06.	Q2	4/2020-6/2020	178,807	1,014,460	59,602	338,153	397,756	-0.8%	0.8%	59,883	335,782	0.4%	-1.4%					
07.	Q3	7/2020-9/2020	176,618	1,016,410	58,873	338,803	397,676	-1.2%	0.2%	59,672	336,652	-0.1%	-0.6%					
08.	Q4	10/2020-12/2020	173,572	1,022,951	57,857	340,984	398,841	-1.7%	0.6%	59,110	338,380	-1.1%	0.3%					
09.	Q1	1/2021-3/2021	173,293	1,033,556	57,764	344,519	402,283	-0.2%	1.0%	58,524	340,615	-2.4%	1.4%					
10.	Q2	4/2021-6/2021	172,208	1,033,714	57,403	344,571	401,974	-0.6%	0.0%	57,974	342,219	-3.2%	1.9%					
11.	Q3	7/2021-9/2021	172,079	1,038,181	57,360	346,060	403,420	-0.1%	0.4%	57,596	344,034	-3.5%	2.2%					
12.	Q4	10/2021-12/2021	172,399	1,043,297	57,466	347,766	405,232	0.2%	0.5%	57,498	345,729	-2.7%	2.2%					
13.	Q1	1/2022-3/2022	172,941	1,055,013	57,647	351,671	409,318	0.3%	1.1%	57,469	347,517	-1.8%	2.0%					
14.	Q2	4/2022-6/2022	171,993	1,054,125	57,331	351,375	408,706	-0.5%	-0.1%	57,451	349,218	-0.9%	2.0%					
15.	Q3	7/2022-9/2022	170,810	1,053,570	56,937	351,190	408,127	-0.7%	-0.1%	57,345	350,500	-0.4%	1.9%					
16.	Q4	10/2022-12/2022	170,183	1,055,359	56,728	351,786	408,514	-0.4%	0.2%	57,161	351,506	-0.6%	1.7%					
17.	Best Current Estimate (average of the four most recent quarters)											57,161	351,506					

Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
Revenues			
01.	Carryforward from prior year (available cash on hand at 4/1/22)	\$488,785	
02.	Prior Year Reconciliation: VVPP assessment collections 4/1/22-6/30/22	\$501,979	
03.	VVPP assessment collections over reconciliation period 7/1/22-3/31/23	\$10,013,367	
04.	Estimated VVPP assessment collections 4/1/23-6/30/23	\$3,337,789	
05.	Total Revenues		\$14,341,921
Expenditures / Allowances			
06.	Prior Year Reconciliation: vaccine purchase 4/1/22-6/30/22	-\$218,518	
07.	Total vaccine purchases 7/1/22-3/31/23	\$12,054,747	
08.	Estimated vaccine purchase 4/1/23-6/30/23	281,601	
09.	Prior Year Reconciliation: KidsVax 4/1/22-6/30/22	-\$11,420	
10.	KidsVax 7/1/22-3/31/23	\$218,493	
11.	Estimated KidsVax 4/1/23-6/30/23	\$35,460	
12.	Prior Year Reconciliation: VDH operational cost 1/1/22-6/30/22	\$7,582	
13.	VDH operational cost 7/1/22-3/31/23	\$201,462	
14.	Estimated VDH operational cost 4/1/23-6/30/23	\$77,220	
15.	Total Expenditures/Allowances		<u>-\$12,646,628</u>
16.	Vaccine Fund Carryforward ¹ (applied to reduce this year's assessment)		\$1,695,292

Notes: ¹ Excess of revenue over expenditures.

Column →
Line ↓

	A	B	C	D	E	F	G	H
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY24 estimated doses	FFY24 estimated cost	FFY23 estimated doses	FFY23 actual doses distributed 10/1/22-3/30/23	Actual/Estimate as a %
01.	COVID	multiple tbd	\$100.000	50,000	\$ 5,000,000	n/a	n/a	n/a
02.	DTaP	Daptacel	\$20.762	2,700	\$ 56,057	1000	1190	119%
03.		Infanrix	\$21.093	2,500	\$ 52,733	4000	1430	36%
04.	DTaP-HepB-IPV	Pediarix	\$64.254	1,200	\$ 77,105	5000	470	9%
05.	DTaP-IPV/Hib	Pentacel	\$68.250	5,000	\$ 341,250	6000	2365	39%
06.	DTaP-IPV-Hib-HepB	Vaxelis	\$97.790	12,000	\$ 1,173,480	6500	5620	86%
07.	DTaP-IPV	Kinrix	\$46.960	2,500	\$ 117,400	4500	1250	28%
08.		Quadracel	\$46.179	2,700	\$ 124,683	2200	1340	61%
09.	Hib	ActHIB	\$10.776	7,000	\$ 75,432	11000	3230	29%
10.		PedvaxHIB	\$15.664	0	\$ -	0	0	n/a
11.		Hiberix	\$10.764	0	\$ -	0	0	n/a
12.	HepA	Vaqta	\$23.300	100	\$ 2,330	500	40	8%
13.		Havrix	\$23.001	13,000	\$ 299,013	14000	5710	41%
14.	HepB	Recombivax	\$13.930	5,200	\$ 72,436	5200	2310	44%
15.		Engerix B	\$16.891	1,000	\$ 16,891	1000	380	38%
16.	HPV	Gardasil	\$224.630	14,000	\$ 3,144,820	14000	5780	41%
17.	IPV	IPOL	\$15.930	2,200	\$ 35,046	2200	1000	45%
18.	Influenza	Fluzone – Quad		0	\$ -	9000	8940	99%
19.				\$14.655	34,500	\$ 505,598	12000	12000
20.		FluMist	\$19.510	1,500	\$ 29,265	2000	1500	75%
21.		Fluarix	\$15.216	12,000	\$ 182,592	18000	18000	100%
22.		FluLaval	\$15.216	12,000	\$ 182,592	24000	24000	100%
23.	MMR	MMR II	\$24.955	7,650	\$ 190,906	7650	2640	35%
24.	MMRV	ProQuad	\$165.094	7,500	\$ 1,238,205	7500	2740	37%
25.	MCV4 / MenACWY	MenQuadfi	\$107.838	12,000	\$ 1,294,056	12000	5355	45%
26.		Menveo	\$105.600	50	\$ 5,280	50	5	10%
27.	MENB	Trumenba	\$130.770	0	\$ -	0	0	n/a
28.		Bexsero	\$141.709	2,000	\$ 283,418	3000	734	24%
29.	PCV13	Prevnar 13	\$158.180	0	\$ -	24000	3700	15%
30.	PCV15	Vaxneuvance	\$162.270	22,000	\$ 3,569,940	0	6600	n/a
31.	PPSV23	Pneumovax 23	\$65.800	60	\$ 3,948	60	20	33%
32.	RV	RotaTeq	\$79.240	8,000	\$ 633,920	8000	2970	37%
33.		Rotarix	\$105.454	6,000	\$ 632,724	6000	2710	45%
34.	Td	TDVAX	\$18.509	200	\$ 3,702	400	94	24%
35.	Tdap	Boostrix	\$36.005	9,000	\$ 324,045	9000	4700	52%
36.		Adacel	\$35.682	5,000	\$ 178,410	5000	2030	41%
37.	VAR	Varivax	\$132.420	7,000	\$ 926,940	7000	2710	39%
					\$ 20,774,216			

¹ CDC pediatric vaccine contract prices as of 4/1/23

Estimated VFC portion

54% \$ 11,218,077

22-23 flu season distribution 9/1/22-3/30/23

Column →
Line ↓

	A	B	C	D	E	F	G	H
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY24 estimated doses	FFY24 estimated cost	FFY23 estimated doses	FFY23 actual doses distributed 10/1/22-3/30/23	Actual/Estimate as a %
01.	COVID	multiple tbd	\$100.000	50,000	\$5,000,000	n/a	n/a	n/a
02.	HepA	Vaqta	\$38.170	2,000	\$76,340	2600	860	33%
03.		Havrix	\$38.569	1,000	\$38,569	1500	420	28%
04.	HepB	Engerix B	\$36.223	4,000	\$144,892	2500	1640	66%
05.		HepLisav-B	\$74.940	1,500	\$112,410	1500	565	38%
06.	HepA-HepB	Twinrix	\$67.923	1,600	\$108,677	1200	730	61%
07.	HPV	Gardasil	\$164.560	2,500	\$411,400	4000	880	22%
08.	Influenza	Fluarix	\$13.916	20,000	\$278,320	15000	15000	100%
09.		FluLaval	\$13.916	20,000	\$278,320	26000	26000	100%
10.		Fluzone syr	\$14.906	10,000	\$149,060	4000	3990	100%
11.	MMR	MMR II	\$55.890	400	\$22,356	500	140	28%
12.	MCV4 / MenACWY	MenQuadfi*	\$80.236	600	\$48,142	1200	120	10%
13.		Menveo	\$76.230	50	\$3,812	0	5	n/a
14.	MENB	Trumenba	\$102.850	0	\$0	0	0	n/a
15.		Bexsero	\$118.367	400	\$47,347	500	103	21%
16.	PCV15	Vaxneuvance	\$149.900	50	\$7,495	400	50	13%
17.	PCV20	Prevnar 20	\$172.996	8,000	\$1,383,968	4000	3840	96%
18.	PPSV23	Pneumovax 23	\$75.630	50	\$3,782	2000	27	1%
19.	RSV	tbd	\$150.000	2,000	\$300,000	n/a	n/a	n/a
20.	RZV	Shingrix	\$104.530	25,000	\$2,613,250	37500	9726	26%
21.	Td	TDVAX	\$17.278	5,000	\$86,390	6100	2354	39%
22.	Tdap	Boostrix	\$27.214	15,000	\$408,210	15000	5470	36%
23.		Adacel	\$27.914	4,300	\$120,030	4300	1880	44%
24.	VAR	Varivax	\$96.650	200	\$19,330	200	40	20%
					\$11,662,098			

¹ CDC adult vaccine contract purchase prices as of 4/1/23 (subject to change 7/1/23)
22-23 flu season distribution 9/1/22-3/30/23

estimated 317

\$323,378